. With MediSource and Pantheon not appearing to be

Quote:

---

. With MediSource and Pantheon not appearing to be “profitable” as stated, how is the following compensation to Travis Bird a good value for Gnbt shareholders?

“At closing, Mr. Bird will enter into an 18-month consulting agreement with NDS. As compensation, Mr. Bird will receive Generex common stock with a value of $250,000, as well as monthly payments equaling $97,222. The monthly payments shall be paid from any available cash from the operations of Pantheon and MediSource. Any remaining balance of such monthly payments will consist of common stock. The agreement specifies the shares are to be freely tradeable. In addition, Mr. Travis will agree to fully assign and exchange any ownership rights in any new technology he develops with the Company, in exchange for a payment of $500,000 in value of common stock for each completed item submitted to the FDA.”


Read More: https://investorshangout.com/post/view?id=562...z7uqj9fIgc

---